Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Tricida, Inc..
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 Nov 2022, 19:13.
ORBIMED ADVISORS LLC - 22 Nov 2022 Form 4 Insider Report for Tricida, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 22 Nov 2022
- Net transaction value
- -$2,205,635
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2022, 19:13:12 UTC
- Prior SEC filing
- 10 Nov 2022
- Next SEC filing
- 29 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Tricida, Inc. on 25 Nov 2022.
Change
- Previous filing in this sequence was filed on 10 Nov 2022.
- Current net transaction value: -$2,205,635.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCDA
transaction
Common Stock
Sale
- Transaction value
- $227,573
- Shares
- -1,034,421
- Change %
- -10%
- Price
- $0.2200*
- Shares after
- 9,246,526
- Date
- 22 Nov 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3
TCDA
transaction
Common Stock
Sale
- Transaction value
- $1,179,633
- Shares
- -5,617,300
- Change %
- -61%
- Price
- $0.2100*
- Shares after
- 3,629,226
- Date
- 23 Nov 2022
- Ownership
- See Footnotes
- Footnotes
- F2, F3
TCDA
transaction
Common Stock
Sale
- Transaction value
- $798,430
- Shares
- -3,629,226
- Change %
- -100%
- Price
- $0.2200*
- Shares after
- 0
- Date
- 25 Nov 2022
- Ownership
- See Footnotes
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the weighted average sale price of the shares of the Issuer's common stock ("Shares") sold, ranging from a low of $0.21 to a high of $0.22 per Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares sold at each separate price.
Footnote F2
The Shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V.
Footnote F3
This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated David Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.